Discovery and validation of graft-versus-host disease biomarkers
about
Graft-versus-host disease biomarkers: omics and personalized medicineGraft-versus-host disease affecting oral cavity. A reviewAcute graft-versus-host disease: a bench-to-bedside update.New insight for the diagnosis of gastrointestinal acute graft-versus-host diseaseVorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialBiomarkers for fatal immune response to stem cell treatment could reduce mortality.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation.An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study.ST2: the biomarker at the heart of GVHD severityA refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.Advances in understanding the pathogenesis of graft-versus-host disease.Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host DiseaseGenetic Background of Immune Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children.Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD.Advances in the treatment of acute graft-versus-host disease.Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease?Transplant biomarkers ready for the clinic?ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathAdult human mesenchymal stromal cells and the treatment of graft versus host disease.Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation.Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease.Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization.Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease.Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
P2860
Q26824540-8ABFFF16-5EB2-4586-A278-C9B3BEA7CC23Q27004303-DB8D1926-1584-4C40-A874-17FBE9252575Q27687130-5BA72651-B045-4716-8401-232CC50FF157Q28238251-9F758AF8-C40F-4E54-A900-131274AA6CACQ33411822-5F041D2C-B857-47F2-BE40-9D309B0C0F46Q33563471-97E3E92B-B27F-4443-AF5A-FDDF996C512AQ33625948-C76AFCB8-6785-4CF8-8F87-FE2B861BA38AQ33648765-667E9698-6EBF-48A5-B9DD-4C1D51733C80Q33798102-A654CE02-B4E6-4A57-8B41-9FF28C3CC948Q33886907-403CAF77-7C62-4206-AEC2-D51DFF37FC80Q34093615-6BC11F6E-E57B-4B9C-BE66-CEE9CB878D23Q34418691-DE9B79A4-E1CD-41D1-BE8C-57E69549B621Q34802351-549F1942-6C0A-4026-894B-F352390E20A9Q35177453-8E8E6A56-B9F2-4FD8-8184-86B017C0A801Q35180727-910829B7-080B-4037-922E-D3EDB3C7B445Q35820356-628823B5-415A-4597-B2B3-C6DADCE9FCBFQ35971439-3423B056-DCBA-4FC3-A226-EDC00D030BDAQ36039542-013ED663-AAC0-41CD-ACC7-27AFB6E89CDBQ36531585-71CFE453-5542-4849-B23E-5AF939D44306Q36543686-39BC155B-6899-41E6-83C6-F7890929C4FBQ36925951-75C60495-00CE-4E8D-81EC-3D732BF0E561Q36980277-C7BC90A8-D310-4415-8E60-2713C96DA73BQ37150078-5AC38DDA-F8C5-4CEC-B938-8600011CBAB9Q37191057-E805C087-F414-44F5-B58B-F159F36F8403Q37291611-1AE8D778-7085-4E6B-A409-32E7EE82770CQ37352764-B012CAD4-82BA-4FAD-8167-A7826D2C971EQ37585026-6F76B56E-AB0F-4AC4-B0E3-0CCDCB119697Q37618997-E72B64F6-F001-4D97-B181-BA133908B55CQ37622055-EAD424C6-FC43-4054-9BCA-BD01CEB88C4DQ37710227-80C07644-793D-4D12-A697-6E9FC12A655AQ37718993-29ED61B6-506E-4618-B9E0-4C0C7857A767Q38083604-8937FE52-8C9A-475B-B373-6BF18F74F4DFQ38287009-0A2CAFA2-2827-4E5E-87EE-7F7DB59AB0C8Q38434710-B209A048-5157-4D3F-AC9D-0076D876AAF7Q38635878-7C1C1B02-693D-4ECC-98D5-50C8D1DC690EQ38682125-0FF6357B-DE4B-4CB0-B80B-1D523098AEC7Q38712496-3049A51B-4B9E-4F01-862A-68E754395476Q38800455-C44EF058-2695-4ECC-8D56-C921A8C5BD16Q38816505-72D708AE-F652-44C5-9D6A-755C0552738BQ38858092-CF60FE2D-E12D-4442-A2AC-5082C68EA372
P2860
Discovery and validation of graft-versus-host disease biomarkers
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Discovery and validation of graft-versus-host disease biomarkers
@ast
Discovery and validation of graft-versus-host disease biomarkers
@en
type
label
Discovery and validation of graft-versus-host disease biomarkers
@ast
Discovery and validation of graft-versus-host disease biomarkers
@en
prefLabel
Discovery and validation of graft-versus-host disease biomarkers
@ast
Discovery and validation of graft-versus-host disease biomarkers
@en
P2860
P1433
P1476
Discovery and validation of graft-versus-host disease biomarkers
@en
P2860
P304
P356
10.1182/BLOOD-2012-08-355990
P407
P577
2012-11-19T00:00:00Z